Treatment-Resistant Depression

What Healing TMS Clinic offers for TRD: rTMS therapy (using Brain Ultimate M Series or Sabers Blossom standard rTMS systems, or BrainsWay Deep TMS when clinically indicated) as the primary in-house treatment, plus psychiatric medication management. TRD is our primary clinical indication.

Treatment-resistant depression (TRD) is most commonly defined as a major depressive episode that has not responded to at least two antidepressant trials of adequate dose and adequate duration (typically ≥6 weeks at therapeutic dose) within the current episode.¹ TRD is not a separate DSM-5-TR diagnosis; it is a clinical specifier applied to major depressive disorder when sequential pharmacotherapy fails to produce response or remission.² The STAR*D trial documented that cumulative remission rates fall with each subsequent medication step, reaching approximately 67% only after four sequential trials — and roughly one-third of patients remain symptomatic throughout.³ TRD affects an estimated 30% of adults with MDD and is associated with greater disability, higher suicide risk, and higher healthcare utilization than treatment-responsive depression.

Recognized signs and symptoms

TRD presents with the full DSM-5-TR symptom set for MDD, often with additional features that reflect chronicity:

Persistent core symptoms despite treatment

• Sustained depressed mood and anhedonia through ≥2 adequate medication trials
• Residual sleep disturbance, appetite change, or fatigue
• Continued cognitive dysfunction — slowed processing, indecision, concentration impairment

Markers of chronicity and severity

• Longer current-episode duration (often >12 months)
• History of multiple prior episodes
• Higher suicidal ideation burden than first-episode depression
• Greater functional impairment in work, relationships, and daily activities
• Frequent comorbid anxiety, substance use, or chronic medical illness

Diagnostic criteria

A diagnosis of MDD with treatment resistance requires that the underlying depressive episode meet DSM-5-TR criteria for major depressive disorder,² and that the prescriber confirm:

1. ≥2 antidepressant trials within the current episode
2. Each trial at an adequate dose (manufacturer-recommended therapeutic range)
3. Each trial at adequate duration (typically a minimum of 6 weeks at therapeutic dose)
4. Trials from at least two distinct pharmacologic classes (or a documented adequate augmentation strategy), per most payer and society criteria

Severity is tracked with the PHQ-9, HDRS, or MADRS. This definition is the standard used by insurance carriers, by FDA TMS device labeling generally, and by most clinical trials.⁴ Diagnosis and the TRD specifier are determined by a treating psychiatrist; this page is educational and is not a self-diagnostic tool.

Treatment options at Healing TMS Clinic

For TRD, evidence-based escalation moves beyond serial monotherapy. Options we offer or coordinate include:

• TMS Therapy — first-line evidence-based escalation for TRD. FDA-cleared repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex.⁴ Real-world response rates of approximately 58% and remission rates of approximately 37% in patients who had previously failed multiple antidepressant trials.⁵ iTBS protocols have demonstrated non-inferiority to standard 10 Hz rTMS with shorter session times.⁶
• Medication management — augmentation strategies including atypical antipsychotics (aripiprazole, brexpiprazole, quetiapine), lithium, T3, or combinations selected against prior response and tolerability.
• Adjunctive psychotherapy referrals — CBT, behavioral activation, and IPT through our referral network.

For patients seeking an evidence-based escalation beyond sequential medication trials, TMS Therapy is the most extensively studied non-pharmacologic option with FDA clearance and broad insurance coverage.

When to consider TMS Therapy

TMS is specifically FDA-cleared for adults with MDD who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode.⁴ In TRD specifically, TMS is appropriate when:

• ≥1–2 antidepressant trials at adequate dose and duration have failed (most payers require ≥2)
• The patient has no personal history of seizure disorder and no ferromagnetic implants within ~30 cm of the treatment coil
• The patient is not pregnant (relative contraindication, evaluated individually)
• The patient is medically stable for outpatient daily treatment over 6–9 weeks

Because TMS is focal and non-systemic, it avoids the weight gain, sexual side effects, and sedation that often limit adjunctive pharmacotherapy. The standard course is 36 sessions over 6–9 weeks; full evaluation determines candidacy and protocol. See TMS Therapy for full mechanism, protocol, and safety detail.

Insurance and TMS for treatment-resistant depression

TRD is the indication for which TMS coverage is most established. Medicare covers TMS under a National Coverage Determination, and most major commercial carriers cover TMS for TRD when payer-specific criteria are met — typically documentation of ≥2 failed antidepressant trials, an adequate psychotherapy trial where required, and PHQ-9/HDRS evidence of moderate-to-severe illness.

Prior authorization is standard. Our team manages the verification, documentation gathering, and prior-authorization submission on your behalf — including chart-note formatting, medication-trial logs, and clinical summaries the payer requires. Submit your insurance details through our verification form and we will confirm TMS coverage and your expected out-of-pocket cost before scheduling.

What to expect at your consultation

The initial visit is a diagnostic and treatment-history review with a psychiatrist. We evaluate prior medication trials for adequacy, screen for TMS candidacy, measure severity, and outline a treatment plan. We serve patients across Anaheim, Orange County, and the broader 30-mile radius — including North Long Beach and the western Inland Empire. Schedule a consultation to begin.

References